Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis
Public ClinicalTrials.gov record NCT00625326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of the Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Low doses of topically administered vitamin D analogs have been shown to have an anti-psoriatic effect without the risk of hypercalcemia. Calcipotriol, the most thoroughly studied of the vitamin D analogs, was first approved in Europe in the early 1990s. It has been shown to be comparable or slightly more effective than class II corticosteroid ointments. However, patients had reduced levels of parathyroid hormone; mean serum and urine calcium were increased during treatment and hypercalciuria was observed. These effects were reversible with discontinuation of therapy. Thus, while calcipotriol ointment was shown to be effective, the potential for alterations in calcium homeostasis have limited its use to 100 g of ointment per week (0.5 mg calcipotriol/week). Work has continued on the creation of new vitamin D analogs, such as COL-121, with the intent of eliminating the adverse effects of hypercalcemia and hypercalciuria with a compound that is more stable and more easily administered.
Study identification
- NCT ID
- NCT00625326
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 321 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2008 (Type not available)
- Primary completion
- Dec 2008 (Actual)
- Completion
- Jun 2009 (Actual)
- Last update posted
- Apr 27, 2011
2008 – 2009
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| East Bay Dermatology Medical Group | Fremont | California | 94538 | — |
| Dermatology Research Associates | Los Angeles | California | 90045 | — |
| Skin Surgery Medical Group, Inc. | San Diego | California | 92117 | — |
| Dermatology Specialists, Inc. | Vista | California | 92083 | — |
| Cherry Creek Research, Inc. | Denver | Colorado | 80209 | — |
| Longmont Medical Research Network | Longmont | Colorado | 80501 | — |
| The Savin Center, PC | New Haven | Connecticut | 06511 | — |
| International Dermatology Research, Inc. | Miami | Florida | 33144 | — |
| MedaPhase, Inc. | Newnan | Georgia | 30263 | — |
| Dermatology Specialists | Louisville | Kentucky | 40202 | — |
| Michigan Center for Skin Care Research | Clinton Township | Michigan | 48038 | — |
| Grekin Skin Institute | Warren | Michigan | 48088 | — |
| Academic Dermatology Associates | Albuquerque | New Mexico | 87106 | — |
| Northwest Cutaneous Research Specialists | Portland | Oregon | 97210 | — |
| Philadelphia Institute of Dermatology | Flourtown | Pennsylvania | 19034 | — |
| DermResearch, Inc. | Austin | Texas | 78759 | — |
| Dermatology Associates of San Antonio | San Antonio | Texas | 78258 | — |
| Dermatology Research Center | Salt Lake City | Utah | 84124 | — |
| The Education & Research Foundation, Inc. | Lynchburg | Virginia | 24501 | — |
| Premier Clinical Research | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00625326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2011 · Synced Nov 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00625326 live on ClinicalTrials.gov.